Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
JAMA|November 29, 2016
Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in WomenOle-Erik Iversen, Maria Jose Miranda, Angels Ulied, et al.
Pediatrics|July 17, 2016
Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical TrialsEdson D Moreira, Stan L Block, Daron Ferris, et al.
Papillomavirus Research (Amsterdam, Netherlands)|July 20, 2017
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trialsLone K Petersen, Jaime Restrepo, Edson D Moreira, et al.
Papillomavirus Research (Amsterdam, Netherlands)|December 23, 2017
Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young womenÁngela María Ruiz-Sternberg, Edson D Moreira, Jaime A Restrepo, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 3, 2014
Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical diseaseElmar A Joura, Kevin A Ault, F Xavier Bosch, et al.
Vaccine|March 7, 2021
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 studyElmar A Joura, Angels Ulied, Corinne Vandermeulen, et al.
Papillomavirus Research (Amsterdam, Netherlands)|October 28, 2017
Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by regionXavier Castellsagué, Kevin A Ault, F Xavier Bosch, et al.
The New England Journal of Medicine|February 19, 2015
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in womenElmar A Joura, Anna R Giuliano, Ole-Erik Iversen, et al.
Lancet (London, England)|September 10, 2017
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trialWarner K Huh, Elmar A Joura, Anna R Giuliano, et al.
Obstetrics and Gynecology|July 12, 2018
Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of AgeSuzanne M Garland, Elmar A Joura, Kevin A Ault, et al.
Pageof 7